Co-Founder And Co-Ceo
CurrentVEL Sciences is a revolutionary biotechnology company. We are an early stage, pre-clinical, biopharma platform developing immune-based prophylactic and therapeutic treatments for cancer and vaccines against antigenically variable pathogens (AVPs) and diseases (HCV, HIV, TB, Coronavirus, malaria, influenza, dengue/zika, etc.). The revolutionary vaccine approach is based on a new class of vaccine immunogens, called Variable Epitope Libraries TM©, or (VELs TM©).In layman terms, VELs create coding of the millions of permutations and variations of responses to changes in viruses. VELs are then embedded into the vaccine and introduced into the body.VELs trigger B cell and T cell memory responses and then the immunological escape is avoided as the new variant faces the corresponding epitope in the immunological process. . . . please go to our website for more information